Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37


Synergistic meropenem-tobramycin combination dosage regimens against clinical hypermutable Pseudomonas aeruginosa at simulated epithelial lining fluid concentrations in a dynamic biofilm model.

Bilal H, Bergen PJ, Kim TH, Chung SE, Peleg AY, Oliver A, Nation RL, Landersdorfer CB.

Antimicrob Agents Chemother. 2019 Aug 19. pii: AAC.01293-19. doi: 10.1128/AAC.01293-19. [Epub ahead of print]


Rational Combinations of Polymyxins with Other Antibiotics.

Bergen PJ, Smith NM, Bedard TB, Bulman ZP, Cha R, Tsuji BT.

Adv Exp Med Biol. 2019;1145:251-288. doi: 10.1007/978-3-030-16373-0_16. Review.


History, Chemistry and Antibacterial Spectrum.

Velkov T, Thompson PE, Azad MAK, Roberts KD, Bergen PJ.

Adv Exp Med Biol. 2019;1145:15-36. doi: 10.1007/978-3-030-16373-0_3. Review.


Synergistic Killing of Polymyxin B in Combination With the Antineoplastic Drug Mitotane Against Polymyxin-Susceptible and -Resistant Acinetobacter baumannii: A Metabolomic Study.

Tran TB, Bergen PJ, Creek DJ, Velkov T, Li J.

Front Pharmacol. 2018 Apr 16;9:359. doi: 10.3389/fphar.2018.00359. eCollection 2018.


Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens.

Tran TB, Wang J, Doi Y, Velkov T, Bergen PJ, Li J.

Front Microbiol. 2018 Apr 12;9:721. doi: 10.3389/fmicb.2018.00721. eCollection 2018.


Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model.

Bilal H, Peleg AY, McIntosh MP, Styles IK, Hirsch EB, Landersdorfer CB, Bergen PJ.

J Antimicrob Chemother. 2018 Jun 1;73(6):1570-1578. doi: 10.1093/jac/dky045.


Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.

Yadav R, Rogers KE, Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00078-18. doi: 10.1128/AAC.00078-18. Print 2018 May.


Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.

Landersdorfer CB, Rees VE, Yadav R, Rogers KE, Kim TH, Bergen PJ, Cheah SE, Boyce JD, Peleg AY, Oliver A, Shin BS, Nation RL, Bulitta JB.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02055-17. doi: 10.1128/AAC.02055-17. Print 2018 Apr.


Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.

Bergen PJ, Bulitta JB, Sime FB, Lipman J, McGregor MJ, Millen N, Paterson DL, Kirkpatrick CMJ, Roberts JA, Landersdorfer CB.

Diagn Microbiol Infect Dis. 2018 May;91(1):69-76. doi: 10.1016/j.diagmicrobio.2017.12.019. Epub 2018 Jan 3.


Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae.

Zhao M, Bulman ZP, Lenhard JR, Satlin MJ, Kreiswirth BN, Walsh TJ, Marrocco A, Bergen PJ, Nation RL, Li J, Zhang J, Tsuji BT.

J Antimicrob Chemother. 2017 Jul 1;72(7):1985-1990. doi: 10.1093/jac/dkx070.


Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.

Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Rogers KE, McGregor MJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02642-16. doi: 10.1128/AAC.02642-16. Print 2017 May.


Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?

Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ, Li J.

Int J Antimicrob Agents. 2016 Dec;48(6):592-597. doi: 10.1016/j.ijantimicag.2016.09.010. Epub 2016 Oct 18. Review.


An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.

Schneider EK, Azad MA, Han ML, Tony Zhou Q, Wang J, Huang JX, Cooper MA, Doi Y, Baker MA, Bergen PJ, Muller MT, Li J, Velkov T.

ACS Infect Dis. 2016 Jul 8;2(7):478-88. doi: 10.1021/acsinfecdis.6b00035. Epub 2016 May 17.


Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.

Bergen PJ, Bulitta JB, Kirkpatrick CM, Rogers KE, McGregor MJ, Wallis SC, Paterson DL, Lipman J, Roberts JA, Landersdorfer CB.

J Antimicrob Chemother. 2016 Sep;71(9):2509-20. doi: 10.1093/jac/dkw153. Epub 2016 May 26.


Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.

Walsh CC, Landersdorfer CB, McIntosh MP, Peleg AY, Hirsch EB, Kirkpatrick CM, Bergen PJ.

J Antimicrob Chemother. 2016 Aug;71(8):2218-29. doi: 10.1093/jac/dkw115. Epub 2016 Apr 26.


Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii.

Tran TB, Cheah SE, Yu HH, Bergen PJ, Nation RL, Creek DJ, Purcell A, Forrest A, Doi Y, Song J, Velkov T, Li J.

J Antibiot (Tokyo). 2016 Jun;69(6):415-21. doi: 10.1038/ja.2015.127. Epub 2015 Dec 16.


Safe disposal of prescribed medicines.

Bergen PJ, Hussainy SY, George J, Kong DC, Kirkpatrick CM.

Aust Prescr. 2015 Jun;38(3):90-2. Epub 2015 Jun 1. Review.


Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria.

Bergen PJ, Bulman ZP, Landersdorfer CB, Smith N, Lenhard JR, Bulitta JB, Nation RL, Li J, Tsuji BT.

Infect Dis Ther. 2015 Dec;4(4):391-415. doi: 10.1007/s40121-015-0093-7. Epub 2015 Dec 8.


In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.

Walsh CC, McIntosh MP, Peleg AY, Kirkpatrick CM, Bergen PJ.

J Antimicrob Chemother. 2015 Nov;70(11):3042-50. doi: 10.1093/jac/dkv221. Epub 2015 Jul 24.


Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two 'old' antibiotics-polymyxin B and chloramphenicol.

Abdul Rahim N, Cheah SE, Johnson MD, Yu H, Sidjabat HE, Boyce J, Butler MS, Cooper MA, Fu J, Paterson DL, Nation RL, Bergen PJ, Velkov T, Li J.

J Antimicrob Chemother. 2015 Sep;70(9):2589-97. doi: 10.1093/jac/dkv135. Epub 2015 May 28.


Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.

Ly NS, Bulitta JB, Rao GG, Landersdorfer CB, Holden PN, Forrest A, Bergen PJ, Nation RL, Li J, Tsuji BT.

J Antimicrob Chemother. 2015 May;70(5):1434-42. doi: 10.1093/jac/dku567. Epub 2015 Feb 23.


Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.

Bergen PJ, Bulman ZP, Saju S, Bulitta JB, Landersdorfer C, Forrest A, Li J, Nation RL, Tsuji BT.

Pharmacotherapy. 2015 Jan;35(1):34-42. doi: 10.1002/phar.1537. Review.


Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.

Lora-Tamayo J, Murillo O, Bergen PJ, Nation RL, Poudyal A, Luo X, Yu HY, Ariza J, Li J.

J Antimicrob Chemother. 2014 Sep;69(9):2434-42. doi: 10.1093/jac/dku151. Epub 2014 May 15.


The after-life of drugs: a responsible care initiative for reducing their environmental impact.

Bergen PJ, Appel SE.

Med J Aust. 2014 Feb 3;200(2):83. No abstract available.


PK/PD models in antibacterial development.

Velkov T, Bergen PJ, Lora-Tamayo J, Landersdorfer CB, Li J.

Curr Opin Microbiol. 2013 Oct;16(5):573-9. doi: 10.1016/j.mib.2013.06.010. Epub 2013 Jul 18. Review.


Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model.

Lee HJ, Bergen PJ, Bulitta JB, Tsuji B, Forrest A, Nation RL, Li J.

Antimicrob Agents Chemother. 2013 Aug;57(8):3738-45. doi: 10.1128/AAC.00703-13. Epub 2013 May 28.


'Old' antibiotics for emerging multidrug-resistant bacteria.

Bergen PJ, Landersdorfer CB, Lee HJ, Li J, Nation RL.

Curr Opin Infect Dis. 2012 Dec;25(6):626-33. doi: 10.1097/QCO.0b013e328358afe5. Review.


Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?

Bergen PJ, Landersdorfer CB, Zhang J, Zhao M, Lee HJ, Nation RL, Li J.

Diagn Microbiol Infect Dis. 2012 Nov;74(3):213-23. doi: 10.1016/j.diagmicrobio.2012.07.010. Epub 2012 Sep 6. Review.


The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model.

Deris ZZ, Yu HH, Davis K, Soon RL, Jacob J, Ku CK, Poudyal A, Bergen PJ, Tsuji BT, Bulitta JB, Forrest A, Paterson DL, Velkov T, Li J, Nation RL.

Antimicrob Agents Chemother. 2012 Oct;56(10):5103-12. doi: 10.1128/AAC.01064-12. Epub 2012 Jul 16.


Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.

Bergen PJ, Tsuji BT, Bulitta JB, Forrest A, Jacob J, Sidjabat HE, Paterson DL, Nation RL, Li J.

Antimicrob Agents Chemother. 2011 Dec;55(12):5685-95. doi: 10.1128/AAC.05298-11. Epub 2011 Sep 12.


Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.

Bergen PJ, Forrest A, Bulitta JB, Tsuji BT, Sidjabat HE, Paterson DL, Li J, Nation RL.

Antimicrob Agents Chemother. 2011 Nov;55(11):5134-42. doi: 10.1128/AAC.05028-11. Epub 2011 Aug 29.


Dosing of colistin-back to basic PK/PD.

Bergen PJ, Li J, Nation RL.

Curr Opin Pharmacol. 2011 Oct;11(5):464-9. doi: 10.1016/j.coph.2011.07.004. Epub 2011 Aug 9. Review.


Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model.

Bergen PJ, Bulitta JB, Forrest A, Tsuji BT, Li J, Nation RL.

Antimicrob Agents Chemother. 2010 Sep;54(9):3783-9. doi: 10.1128/AAC.00903-09. Epub 2010 Jun 28.


Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model.

Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW.

J Antimicrob Chemother. 2008 Mar;61(3):636-42. doi: 10.1093/jac/dkm511. Epub 2008 Jan 28.


Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.

Bergen PJ, Li J, Rayner CR, Nation RL.

Antimicrob Agents Chemother. 2006 Jun;50(6):1953-8.


Evidence for 5-HT7 receptors mediating relaxation of human colonic circular smooth muscle.

Prins NH, Briejer MR, Van Bergen PJ, Akkermans LM, Schuurkes JA.

Br J Pharmacol. 1999 Oct;128(4):849-52.


Prejunctional muscarinic (M1)-receptor interactions on guinea-pig ileum: lack of effect of cisapride.

Schuurkes JA, Van Bergen PJ, Van Nueten JM.

Br J Pharmacol. 1988 May;94(1):228-34.

Supplemental Content

Loading ...
Support Center